
Strados Labs is a medical technology company focused on improving the quality of life for patients with chronic respiratory diseases through its innovative RESP® Biosensor. This device continuously captures lung sounds, such as cough and wheeze, providing objective, time-stamped data that enhances clinical care and research studies. The company differentiates itself with its FDA-cleared technology, which is designed for daily life and offers a low-burden, discreet solution for patients. With over 750,000 lung sounds and 20 million breaths captured across four continents, Strados Labs is positioned as a leader in remote respiratory monitoring, helping healthcare providers and life sciences companies better understand treatment responses and prevent hospitalizations.

Strados Labs is a medical technology company focused on improving the quality of life for patients with chronic respiratory diseases through its innovative RESP® Biosensor. This device continuously captures lung sounds, such as cough and wheeze, providing objective, time-stamped data that enhances clinical care and research studies. The company differentiates itself with its FDA-cleared technology, which is designed for daily life and offers a low-burden, discreet solution for patients. With over 750,000 lung sounds and 20 million breaths captured across four continents, Strados Labs is positioned as a leader in remote respiratory monitoring, helping healthcare providers and life sciences companies better understand treatment responses and prevent hospitalizations.
Product: RESP® wearable lung-sound biosensor plus cloud platform for continuous respiratory monitoring
Regulatory status: FDA 510(k) clearance(s) and CE mark
Use cases: Remote patient monitoring, clinical research, and care
Latest funding: Convertible note announced Mar 15, 2024 (lead: SOSV)
Chronic respiratory disease monitoring and remote respiratory assessment for healthcare and life-sciences research.
2016
Medical technology / Digital health
Round listed with SOSV as lead; HAX also participated
4500000.00
Announced as a $4.5M pre-series A funding round with investors including SOSV, cultivate(MD), Wavemaker360 Health, Blu Venture Investors, and Broad Street Angels
“Backed by institutional investors and health-focused VCs including SOSV (and HAX), Blu Venture Investors, cultivate(MD), Wavemaker360 Health, Broad Street Angels, plus SBIR/NSF grant funding”